Dr.Sandeep.M Junior resident Dr.Ajaykumar Prof & HOD.

Slides:



Advertisements
Similar presentations
CLINICAL TRIALS IN CERVICAL CANCER Cancer Institute (WIA) experience.
Advertisements

Pulmonary Stereotactic Ablative Radiotherapy:
I I. B.- T R E A T M E N T P L A N: DOCETAXEL 75 mg/m2 40 mg/m2 THORACIC RT (66 Gys: 180 cGy/d) CISPLATIN 40 mg/m2 Days E V A L U A.
Rectal Cancer: Advanced Technologies Chris Willett, M.D. Department of Radiation Oncology Duke University Medical Center Durham, NC.
Age as a prognostic factor for head and neck squamous cell carcinoma: should older patients be treated differently? Udi Cinamon 1, Michael P. Hier 2, Martin.
P. Singh 1, A. Necchi 2, P. Giannatempo 2, G. Niegisch 3, G. di Lorenzo 4, C. Hsu 1, G. Sonpavde 5 University of Arizona Cancer Center 1, Tucson; Fondazione.
Incorporating Cesium-131 Interstitial Implants into Daily Clinical Practice: How to Make Radiation appear exactly where you want. Jonathan Feddock, MD.
21th WCC, Shenzhen, China, Aug 19, 2010 Guo-Liang Jiang, MD, FACR Min Fan, MD, Jiayan Chen, MD Fudan University Shanghai Cancer Center Combination of radiation.
Anal Cancer Rob Glynne-Jones Mount Vernon Cancer Centre on behalf of NCRI anal cancer subgroup.
Postoperative Radiation for Oral Cavity Squamous Cell Carcinoma: The EP.
Surgical resection of metastatic GIST on imatinib delays recurrence and death: results of a cross- match comparison in the EORTC Intergroup study.
Mary McCormack & Jonathan Ledermann NCRI Gynae Clinical Studies Group.
Successful treatment of pediatric desmoid tumors using hydroxyurea Naomi Balamuth, M.D. Richard Womer, M.D. November 13, 2008.
PREOPERATIVE HYPOFRACTIONED RADIOTHERAPY IN LOCALIZED EXTREMITY/TRUNK WALL SOFT TISSUE SARCOMAS EARLY STUDY RESULTS Hanna Kosela; Milena Kolodziejczyk;
Intra-Operative Radiation Therapy for Treatment of Early Stage Breast Cancer: Short Term Results from a Single Institution Clinical Trial Using Electronic.
TIRADS III nodules on ultrasound of thyroid
CET Cancer Center Oakland California High Dose Rate (HDR) Brachytherapy Gynecological Cancer D. Jeffrey Demanes M.D
Radiothérapie Hypofractionnée et Cancer de Prostate
Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium to Prevent Oxaliplatin- Induced Sensory Neurotoxicity, N08CB.
Experience and Outcomes with Hypofractionated Concurrent Chemoradiation for Stage III NSCLC at NCCC Gregory Webb Medical Student.
A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities.
Prevention by intravesical hyaluronic acid (Cystistat®) of acute radiation-induced cystitis in radiotherapeutic management of cervical cancer E. González.
Sequential vs. concurrent chemoradiotherapy for locally advanced non-small cell carcinoma.
Pneumonectomy for Locally Advanced Lung Cancer after Neoadjuvant Concurrent Chemo-radiation Therapy K. Okabe, H. Tao, T. Tanaka, T. Hayashi, K. Yoshiyama,
1 Phase II trial of sequential gemcitabine and carboplatin followed by paclitaxel as first-line treatment of advanced urothelial carcinoma Presented by.
Long-term follow-up of a prospective trial of pre-operative external-beam radiation and post-operative brachytherapy for retroperitoneal sarcoma LA Mikula,
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Clinico-Dosimetric Correlation for Acute and Chronic Gastrointestinal Toxicity in Patients of Locally Advanced Carcinoma Cervix Treated With Conventional.
Definitive chemo-radiotherapy for esophageal cancer; failure pattern and salvage treatments Ryuta Koike, Y. Nishimura, K. Nakamatsu, S. Kanamori, M. Okubo,
Decreased Risk of Radiation Pneumonitis With Coincident Concurrent Use Of Angiotensin- Converting Enzyme Inhibitors In Patients Receiving Lung Stereotactic.
A phase I dose escalation study of Nimotuzumab in combination with concurrent chemoradiation for patients with locally advanced squamous cell carcinoma.
Histopathological evaluation of lymphatic nodules in cancer of the uterine cervix Coordinators: First Author: Asist. Univ. Dr. Chira Liliana Stud. Bogdan.
Prospective Phase I/II Trial of Carbon Ion Radiotherapy for Locally Advanced Non-small-cell Lung Cancer (NSCLC) Abstract title: CIRT for Locally Advanced.
Targeted Intraoperative Radiotherapy versus Whole Breast Radiotherapy for Breast Cancer (TARGIT-A Trial): An International, Prospective, Randomised, Non-Inferiority.
Comparison of SIB-IMRT and Conventional Accelerated Hyper-fractionated IMRT With Concurrent Cisplatin and Etoposide for Limited Disease SCLC Baosheng Li.
Mahatma Gandhi Cancer Hospital and Research Institute Dr P. S. Bhattacharyya, MD Radiation Oncologist. Elekta Synergy CT Simulator Flexitron HDR.
THE OUTBACK TRIAL A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared.
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, Ronald Feld, Natasha B Leighl,
Adjuvant High-Dose-Rate Brachytherapy Alone for Stage I/II Endometrial Adenocarcinoma using a 4-Gray versus 6-Gray Fractionation Scheme Marie Lynn Racine,
Stereotactic Ablative Body Radiotherapy for Non small cell lung cancer
Background Carcinoma of the anal canal accounts for 1.5% of all digestive system malignancies in the United States. 1 The annual incidence continues to.
Hormone treatment combined with radiotherapy
High Dose Rate Brachytherapy Boost for Prostate Cancer: Comparison of Two Different Fractionation Schemes Tania Kaprealian 1, Vivian Weinberg 3, Joycelyn.
Radiation Therapy Connective Tissue Oncology Society 2005 Thomas F. DeLaney, M.D.
بسم الله الرحمن الرحيم ” قالوا سبحانك لا علم لنا إلا ما علمتنا إنك أنت العليم الحكيم“
Adjuvant treatment for endometrial cancer Ameri A Associate Professor of Radiation Oncology Shahid Beheshti University of Medical Sciences Dec Pars.
IMPACT OF PHYSICAL DOSE RATE EFFECT ON THE LONG TERM RESULTS OF THE CF-252 BRACHYTHERAPY OF CERVIX CARCINOMA E. Janulionis; K.P.Valuckas; V.Atkocius; V.Samerdokiene.
Outcome of patients treated with Image Guided Brachytherapy for Locally Advanced Carcinoma of the Cervix at Royal Devon & Exeter Hospital Dr.
Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.
To investigate the acute toxicity of 3D conformal concurrent chemo RT (Keeping PTV Dmax
Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.
What Factors Predict Outcome At Relapse After Previous Esophagectomy And Adjuvant Therapy in High-Risk Esophageal Cancer? Edward Yu 1, Patricia Tai 5,
Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.
Cervical Cancer: Experiences from a Cohort of HIV-infected Women Pascoe M, Magure T, Mudhokwani P et al Abstract: MOAB0202.
PHASE II TRIAL OF HYPOFRACTIONATED BREAST IRRADIATION WITH VMAT-SIB TECHNIQUE: TOXICITY AND EARLY CLINICAL ASSESSMENT IN 270 PATIENTS F. De Rose¹, F. Alongi¹,
Image Guided Interstitial Brachytherapy For Locally Advanced Gynaecological Cancer With A MUPIT Applicator M.A.D. Haverkort, MD 1, E. Van der Steen - Banasik,
RANDOMIZED PHASE II STUDY OF NABPACLITAXEL, IN RECURRENT ADVANCED OR METASTATIC CERVICAL CANCER MITO CER-NAB Enrica Mazzoni, MD Medical Oncology & Breast.
Results of Definitive Radiotherapy in Anal Canal Carcinoma
ADSCaN A Randomised Phase II study of Accelerated, Dose escalated, Sequential Chemo-radiotherapy in Non-Small Cell Lung Cancer Rationale: Lung cancer.
นายแพทย์ธราธร ตุงคะสมิต นายแพทย์ชำนาญการพิเศษ โรงพยาบาลมะเร็งอุดรธานี
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
Comparative Results of Vaginal Relapses and Toxicity of Three 192-Ir HDR brachytherapy (BT) Schedules in Postoperative Endometrial Carcinoma (EC). Rovirosa.
Institute of Oncology “Ion Chiricuță”, Cluj, Romania
Evaluation of biologically equivalent dose escalation, clinical outcome, and toxicity in prostate cancer radiotherapy: A meta-analysis of 12,000 patients.
Investigator:- Dr Rita Singh Guide:- Dr Ramesh.S. Bilimaga
ACT II: The Second UK Phase III Anal Cancer Trial
Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemoradiotherapy for locally advanced rectal cancer: safety results of a randomized phase III.
高雄榮民總醫院耳鼻喉頭頸部 林陞樵 林曜祥 康柏皇 張庭碩
Proton Therapy for Thymic Malignancies: Multi-institutional Patterns-of-Care and Early Clinical Outcomes from the Proton Collaborative Group Registry &
Proton Beam Therapy for Liver Cancer is Well Tolerated: Outcomes from the Proton Collaborative Group REG Trial Michael Chuong, M.D.1,2, Smith Apisarnthanarx,
Presentation transcript:

Dr.Sandeep.M Junior resident Dr.Ajaykumar Prof & HOD

Background  Carcinoma cervix is one of the commonest malignancies in females.  Locally advanced carcinoma cervix is managed with concurrent chemoradiation.  Brachytherapy is usually delivered by either HDR or LDR machines.  ABS(American Brachytherapy Society recommeneds maximum 7.5Gy/fr and min 4 fr)1  1 ref:Nag s etal Int J Radiat oncol Biol Phy 2000,48,201

 In high volume centers for adequate use of resources, their were studies assessing HDR ICRT with reduce fractionation schedules  Hama Y et al Radiology ;  6.8x 3f vs 9gy x2  Firuza patel,pankaj kumar et alBrachytherapyBrachytherapy  Volume 10, Issue 2, March–April 2011, Pages 147–153 Volume 10, Issue 2

Aims and Objectives  To compare two different fractionation schedules in high dose brachytherapy for carcinoma cervix with respect to locoregional control of the disease

methodology  Study setting :- Dept. of Radiotherapy Calicut medical college  Study design :- retrospective cohort  Study period : jan – 2011 jan

inclusion criteria  All patients with ca cervix, stage II & III who took treatment from our college  Performance status – 1 & 2  Age between – 35 – 65 years  Squamous cell carcinoma histology

Exclusion criteria  Performance status – 3 & 4  No proper follow up  Age > 65 years  Stage IV disease  Non concurrent EBRT given cases

Materials & methods  124 patients with carcinoma cervix with stage II & III were given concurrent chemo radiotherapy  cisplain 40 mg/m2 weekly  RT dose of 45Gy/23 #

 Patients are divided in 2 arms  7Gy given weekly in 3 sittings  9Gy given weekly in 2 sittings

 All patients are assessed clinically for residual disease after CCRT  All patients are followed up as per guidelines for one year for loco regional recurrence acute complications  Recurrences are confirmed with biopsy

stage StageFrequencyPercent II7661.3% III4832.7% %

ebrt FrequencyPercent 45Gy/23#124100

Residual growth FrequencyPercent present absent6149.2

brachytherapy FrequencyPercent 9GY x GY x

statistics  Data assessed using spss version 16

results

No of recurrences in two arms

No of recurrences according to stage

No of recurrence in comparison with presence of residual disease

stageNADrecurrencetotal II64 (84.2%)12 (15.8%)76 III41 (85.4%)7 (14.6%)48 valuedfAsymp. Sig (2-sided) Pearson chi square

Residual growthNADrecurrencetotal present52 (82.5%)11 (17.5%)63 absent55 (90%)6 (10%)61 valuedfAsymp. Sig. (2-sided) Pearson chi square test

toxicities  Bladder – grade I- 9Gy – 15% 7 Gy- 20%  None of the pts needed intervention for heamatologic toxicities  Bleeding PR one patient from both arms reported bleeding PR was managed conservatively

conclusion  In carcinoma cervix CCRT followed by HDR ICRT with 9Gy wkly in two fraction is equaly effective in local control as 7GYin three fractions in a follow up period of one year  These patients should be followed up for late toxicities

limitations  Not a prospective study  Only short term follow up

Thank u